Expertise in
7
conditions

Dr. Roy M. Fleischmann

Rheumatology
Rheumatology Associates & Subsidiary
8144 Walnut Hill Ln Ste 800, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
7
conditions
Rheumatology Associates & Subsidiary
8144 Walnut Hill Ln Ste 800, 
Dallas, TX 

Overview

Roy Fleischmann is a Rheumatologist practicing medicine in Dallas, Texas.

Dr. Fleischmann is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Arthritis, Psoriatic Arthritis, and Psoriasis.

He is actively involved in clinical research, co-authoring 219 peer reviewed articles and participating in 8 clinical trials.

Specialties

Rheumatology

Licenses

Specialist in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO

Locations

Rheumatology Associates & Subsidiary
8144 Walnut Hill Ln Ste 800, Dallas, TX 75231

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Multipart Exploratory Study to Evaluate Splenic Nerve Stimulation in Patients With Rheumatoid Arthritis
Multipart Exploratory Study to Evaluate Splenic Nerve Stimulation in Patients With Rheumatoid Arthritis
Enrollment Status: Recruiting
Publish Date: May 22, 2024
Intervention Type: Drug, Device
Study Phase: Not Applicable
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug, Other
Study Drug: VIB7734
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: April 23, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of the Safety and Tolerability of Intravenous LLP2A-Alendronate in Adult Men and Women With Osteopenia Secondary to Glucocorticoids
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of the Safety and Tolerability of Intravenous LLP2A-Alendronate in Adult Men and Women With Osteopenia Secondary to Glucocorticoids
Enrollment Status: Completed
Publish Date: August 06, 2021
Intervention Type: Drug
Study Drug: LLP2A-Alendronate
Study Phase: Phase 1
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study
A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study
Enrollment Status: Terminated
Publish Date: October 09, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

219 Total Publications

Response to correspondence on 'Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study' by Mysler et al.
Response to correspondence on 'Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study' by Mysler et al.
Journal: Annals of the rheumatic diseases
Published: May 14, 2026
Similar Doctors
Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required
Before you request

Rheumatology Associates

2021 N MacArthur Blvd, Ste 515, 
Irving, TX 
 (12.6 miles away)
214-540-0700
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Stanley Cohen is a Rheumatologist practicing medicine in Irving, Texas. Dr. Cohen is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Arthritis, Psoriasis, Endoscopy, and Gastrostomy. Dr. Cohen is board certified in Rheumatology- American Board Of Internal Medicine, Rheumatology- American Board Of Internal Med/Rheumatology, Internal Medicine- American Board Of Internal Med, and Internal Medicine- American Board Of Internal Medicine. Dr. Cohen is currently accepting new patients.

Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required
Before you request

Dallas County Hospital District

5200 Harry Hines Blvd, 
Dallas, TX 
 (6.6 miles away)
214-590-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bonnie Bermas is a Rheumatologist practicing medicine in Dallas, Texas. Dr. Bermas is highly rated in 29 conditions, according to our data. Her clinical expertise encompasses Lupus Nephritis, Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Discoid Lupus Erythematosus (DLE). Dr. Bermas is currently accepting new patients.

Expertise in
35
conditions
Expertise in
35
conditions
Referral may be required
Before you request

Rheumatology Associates & Subsidiary

8144 Walnut Hill Ln Ste 800, 
Dallas, TX 
 (0.1 miles away)
214-540-0700
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Wright is a Rheumatologist practicing medicine in Dallas, Texas. Dr. Wright is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis (RA), and Undifferentiated Connective Tissue Disease (UCTD). Dr. Wright is currently accepting new patients.

Frequently Asked Questions about Dr. Roy M. Fleischmann

How do I make an appointment with Dr. Roy M. Fleischmann?

You can book an appointment with Dr. Roy M. Fleischmann by calling their office at 214-540-0700. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Roy M. Fleischmann a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Roy M. Fleischmann is classified as an Elite expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Roy M. Fleischmann specialize in?

While Dr. Roy M. Fleischmann is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Arthritis, and Psoriatic Arthritis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Roy M. Fleischmann participate in research or clinical trials?

Yes. Dr. Roy M. Fleischmann has published 219 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Dr. Roy M. Fleischmann's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Roy M. Fleischmann accept my insurance?

Dr. Roy M. Fleischmann accepts most major insurance plans, including Health Care Services Corporation. We recommend calling the office directly at 214-540-0700 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fleischmann's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile